La Merie Publishing: Market Research Reports

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective This report provides you with a landscape description and an...

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective This report provides you...

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective This report provi...

Report Package: “Drug the Undruggable” Technologies This report package includes four full reports for the price of two: Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a land...

Competitor Analysis: KRAS Inhibitors This Competitive Intelligence report about KRAS Inhibitors evaluates the landscape of investigational small molecules, antibodies, cell therapeutics and vaccines t...

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective This report provides ...

Competitor Analysis: RORgamma Antagonists and Agonists This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting...

Competitor Analysis: TGF-beta/Receptor Inhibitors This Competitive Intelligence report about TGF-beta/Receptor Inhibitors evaluates the landscape of investigational new molecular entities targeting tr...

Report Package: Bispecific Antibodies This report package includes the full report T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis and the ...

... of 38 established or emerging T-cell or NK-cell engaging antibody technologies; Profiles of one approved, 89 T-cell or NK-cell engaging bispecific antibodies in all phases of development, and analysis of eight discontinued bispecific T-cell engagers; Technology selection and ...

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational ...

Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018 This Competitive Intelligence report analyzes the competitive field of CD40, GITR, OX40, 4-1BB, CD27, ICOS ...

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway ... . In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment. Competitor projects are listed in a tabular format providing information on: Drug ...

Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators This product consists of four reports in pdf ... include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of ...

Competitor Analysis: PD-1 and PD-L1 ... specific R&D pipelines of PD-1 and PD-L1 checkpoint inhibitors. Competitor projects are listed in a tabular format providing information ... to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information ...

Competitor Analysis: PRAME-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data. PRAME (preferentially ...

Competitor Analysis: WT1-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of WT1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...

Competitor Analysis: hTERT-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of hTERT-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...

Competitor Analysis: NY-ESO-1-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of NY-ESO-1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...

Competitor Analysis: MAGE-A-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of MAGE-A-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant ...

Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin Intracellular cancer targets are estimated to be 3-4 times more frequent than surface protein targets. However, these ...

Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018 This Competitive Intelligence report analyzes the competitive field of CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors ...

... less successful against solid tumors. This report „TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & ... acquisition prices and financing rounds. Download Sample Pages: TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders ...

Competitor Analysis: Survivin-Targeted Immunotherapy This Competitive Intelligence report analyzes the competitive field of Survivin-Targeted Immunotherapies as of May 2018 in a tabulated format with structured listings of industry-relevant ...

T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of ... or T-cell redirecting bispecific antibodies. This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy ...

... that there are 3-4 times more intracellular targets than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal ... p53 or Ras, β-catenin and Myc. This report „Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell- ...

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update The Competitive Intelligence Report „Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin ...

Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics mRNA is a rather versatile therapeutic ... as a cancer vaccine. The so far modest efficacy of oncolytic viruses still can be improved when combined with immune checkpoint inhibitors. This lead to an increased ...

... ; R&D Pipeline News - Therapeutic Area Edition. After purchase of the Flat-Rate Subscription to La Merie Publishing Reports & News Services , credentials to access a dedicated server ...

... report about Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017 provides a competitor evaluation in the field of antibodies, vaccines and engineered chimeric antigen receptor (CAR) T-cells targeting mesothelin as of August 2017. Mesothelin is a surface ...

... mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals as of June 2017 brings you up-to-date regarding key mRNA players, key mRNA technologies and applications, mRNA vaccines & therapeutics ...

Competitor Analysis: Kallikrein Inhibitors & Bradykinin Receptor Antagonists The present Competitive Intelligence report aboutKallikrein Inhibitors & Bradykinin Receptor Antagonists provides a competitor evaluation in the field of marketed and novel ...

Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017 This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic ...

Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies ...

Competitor Analysis: Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars This Competitive Intelligence report about Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars provides a competitor evaluation in the field of mainly recombinant antibodies, but ...

The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities The field of oncolytic viruses was quite dormant in the first decade of the 2000s ... „The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities“ as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects ...

Competitor Analysis: CSF-1R Antagonists for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of novel colony stimulating receptor 1 (CSF-1R) antagonists for modulation of the immunosuppressive tumor microenvironment as of December 2016. The Competitor Analysis includes antibody-based antagonists of CSF-1R as well as small molecule inhibitors of CSF-1R tyrosine ...

Competitor Analysis: CXCR4 Antagonists for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of novel antagonists of the C-X-C chemokine receptor type 4 (CXCR4) and ... 2016. The Competitor Analysis includes antagonists of CXCR4 based on small molecules, peptides and antibodies as well as inhibitors of CXCL12, the ligand for CXCR4. Included are molecules ...

Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of specific IDO and TDO inhibitors as well as dual ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology This product consists of four reports in pdf ... Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others Targets of Immunomodulators are inhibitory as well as stimulatory immune ...

Competitor Analysis: TGF-β Inhibitors for Modulation of the Tumor Microenvironment This industry report describes the competitive R&D landscape of specific TGF-beta inhibitors as well as TGF-beta receptor antagonists ... 2016. The Competitor Analysis includes antibody-based inhibitors of transforming growth factor beta (TGF-beta) or antagonists of TGF-beta receptors as well as small molecule inhibitors of TGF-beta receptor ...

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPα, Adenosine, STING & Others This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF ... active projects in research and development of modulators of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of Tumor Microenvironment Modulators. Competitor projects are listed in a tabular format ...

... Package: Hot targets for empowered antibody and cell therapy technologies This package contains three reports analyzing BCMA, CD123 and CD22 as versatile and hot targets ... package of the three reports provides a 40% discount on the regular prices: B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities CD123: a paradigmatic target ...

Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates ... -specific R&D pipelines of ADCs. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target/Mechanism of Action, Class of Compound (antibody, linker, payload ...

... Drug Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing's proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project ... a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. Benefits from the R&D Drug Pipeline Database ...

Unbenanntes Dokument Flat-Rate Access to R&D Database & Reports from La Merie Publishing R&D Drug Pipeline Database: 1-Year Subscription Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-year ... . Internet access is the only prerequisite for this service. Upon purchse of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated ...

Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates This pdf ... Pipeline: Anti-CD22 Immunotherapeutics CD-22Targeted Immunotherapeutics include: Naked Antibodies & Combinations Radioimmunotherapeutics Immunotoxins Antibody-Drug Conjugates Autologous CAR T-Cells Information about the anti-CD22 Immunotherapeutics pipeline ...

... : BCMA-Targeted Antibodies & T-Cellls BCMA-Targeted Antibodies & T-Cells include: Autologous & allogeneic T-Cells Bispecific tumor-targeted antibodies & T-cells Bispecific T-Cell and NK-Cell redirecting antibodies Antibody-Drug Conjugates Information about the BCMA-Targeted Antibodies & T-Cells pipeline ...

BCMA-Targeted Immunotherapeutics in: October 2016 R&D and Business Tracker for Bispecific Antibodies This pdf report contains information about Bispecific Antibodies released during the month of October 2016 ... Tracker for Bispecific Antibodies. Featured presentations of October 2016 include the pipeline of B-Cell Maturation Antigen (BCMA)-targeted immunotherapeutics, the profile of German technology company Pieris ...

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment ... , CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for ...